Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryBreast imaging AI suite from DeepHealth that includes Saige-Dx and related mammography workflow modules for AI-assisted screening interpretation and population-health operations.
Breast imaging programs evaluating FDA-cleared mammography AI alongside worklist, density, risk, and operations modules while keeping interpreting physicians accountable for final reads.
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating DeepHealth Breast Suite as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Separate each Breast Suite component before deployment because FDA clearance for Saige-Dx does not automatically cover risk assessment, breast ultrasound, BAC, viewer, or future suite modules. |
|---|---|
| Privacy | Review mammography image routing, cloud processing, PACS or worklist integration, user roles, support access, retention, audit logging, BAA terms, and regional data-processing commitments. |
| Evidence | Pilot against local mammography baselines for cancer detection, recall, reading time, density distribution, subgroup performance, scanner mix, and radiologist disagreement rather than relying on broad suite claims. |
| Workflow | Best governed as radiologist-reviewed breast imaging decision support with module-specific protocols, quality monitoring, override capture, escalation rules, and clear patient communication boundaries. |
DeepHealth describes Breast Suite as a modular AI-powered breast imaging suite; its product page notes FDA 510(k) clearance K251873 for Saige-Dx while also labeling some modules as pending clearance or not cleared for U.S. use. FDA summaries for Saige-Dx describe concurrent reading-aid use for qualified interpreting physicians reviewing screening DBT mammograms with compatible hardware.
Not for: Autonomous breast cancer diagnosis, assuming every Breast Suite module is cleared in every market, unsupported scanners or exam types, or replacing radiologist review and MQSA-governed quality workflows.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.